Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 20, 2023 13:12 ET | Source: Predicine

Predicine Announces New Study Published in The New England Journal of Medicine Demonstrating Clinical Utility of its MRD Liquid Biopsy Assay in Supporting Genentech’s Phase 1 Clinical Trial of Divarasib

HAYWARD, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Predicine, Inc., a pioneer in the field of liquid biopsy, announced a new study published in The New England Journal of Medicine (NEJM),...
April 28, 2023 17:42 ET | Source: Predicine

Predicine to Introduce PredicineALERT™ MRD Assay and Present Two ctDNA Studies in Genitourinary Cancers at AUA 2023 Annual Meeting

HAYWARD, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- Predicine, a global molecular insights company, announced today that it will present two studies and introduce PredicineALERT™ Minimal Residual...
April 14, 2023 16:47 ET | Source: Predicine

Predicine to Introduce PredicineALERT™ MRD Assay and Present Twelve Posters at AACR 2023 Conference

HAYWARD, Calif., April 14, 2023 (GLOBE NEWSWIRE) -- Predicine, a global molecular insights company, announced today that it will present data from 12 studies and introduce PredicineALERT™, a...
February 16, 2023 16:05 ET | Source: Predicine

Predicine to Present Four Studies at 2023 ASCO Genitourinary (GU) Symposium Highlighting the Technical and Clinical Utility of Predicine’s Liquid Biopsy Based Assays

HAYWARD, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Predicine, a global molecular insights company, is committed to advancing genitourinary (GU) cancer detection and treatment decisions through its...
November 10, 2022 21:00 ET | Source: Predicine

Predicine to Introduce PredicineCOMPLETE™, its Genome-Wide Liquid Biopsy Solution, at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

SILICON VALLEY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Predicine, a global molecular insights company, announces the introduction of PredicineCOMPLETE™, the organization’s most comprehensive...
September 20, 2022 09:00 ET | Source: Predicine

Predicine’s Liquid Biopsy Next-Generation Sequencing (NGS) Assay is Granted Breakthrough Device Designation by U.S. Food and Drug Administration

HAYWARD, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Predicine, Inc., a global molecular insights company committed to advancing precision medicine in oncology and infectious diseases, announced...
September 08, 2022 16:00 ET | Source: Predicine

Predicine to Present New Data at ESMO 2022 Demonstrating the Utility of its Portfolio of Liquid Biopsy Tests for Cancer Patients

SILICON VALLEY, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Predicine, Inc., a global molecular insights company, announced today that it will present four posters at the ESMO conference being held...
August 09, 2022 08:00 ET | Source: Predicine

Predicine Expands to Europe with the recently launched CE-Marked cfDNA Assay PredicineCARE™ for Genomic Profiling in Blood and Urine

SILICON VALLEY, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Predicine, Inc., a global molecular insights company, has launched its CE-marked PredicineCARE™ for genomic profiling in blood and urine....
July 25, 2022 08:00 ET | Source: Predicine

Predicine Expands Its Nationwide COVID-19 Testing Capability Through the Recent FDA EUA Authorization of Predicine SARS-CoV-2 RT-PCR Test and Self-Collection Kit

SILICON VALLEY, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Predicine, a global molecular insights company committed to advancing precision medicine in oncology and infectious diseases, announced...

keyboard_arrow_left Previous Page